VPC
FULC icon

Vestal Point Capital’s Fulcrum Therapeutics FULC Stock Holding History

Vestal Point Capital’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.44M Buy
1,100,000
+150,000
+16% +$1.39M 0.24% 68
2025
Q4 		$10.7M Buy
+950,000
New +$9.67M 0.37% 48
2024
Q3 		– Sell
-1,160,000
Closed -$7.19M – 77
2024
Q2 		$7.19M Buy
1,160,000
+465,000
+67% +$3.52M 0.54% 40
2024
Q1 		$6.56M Sell
695,000
-330,000
-32% -$2.95M 0.54% 37
2023
Q4 		$6.92M Buy
+1,025,000
New +$4.55M 0.73% 30

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Vestal Point Capital's FULC Position: Q1 2026 in Review

Vestal Point Capital increased its Fulcrum Therapeutics (FULC) stake by 16% in Q1 2026, buying an estimated $1.39M and bringing the position to 1,100,000 shares worth $8.44M. The position accounts for 0.24% of the portfolio, ranked #68.

Vestal Point Capital first reported a position in FULC in Q4 2023 and has held it in 5 quarters since. The position peaked at $10.7M in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Vestal Point Capital held 1,100,000 shares of Fulcrum Therapeutics worth $8.44M as of Q1 2026.
  • Vestal Point Capital bought 150,000 Fulcrum Therapeutics shares in Q1 2026, an estimated $1.39M.
  • Fulcrum Therapeutics made up 0.24% of Vestal Point Capital's portfolio in Q1 2026, its #68 holding.
  • Vestal Point Capital first reported a position in Fulcrum Therapeutics in Q4 2023 and has held it in 5 quarters since.
  • Vestal Point Capital's Fulcrum Therapeutics position peaked at $10.7M in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Vestal Point Capital's 13F filing for Q1 2026, filed 15 May 2026.